How subcutaneous treatments are helping to impact cancer care

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
Seeking Alpha

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...
Medscape

NHS First in Europe to Offer New Subcutaneous Cancer Jab

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a subcutaneous injectable version of the cancer drug nivolumab (Opdivo, Bristol Myers Squibb). NHS England said it would be ...
Seeking Alpha

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...
Business Wire

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New subcutaneous (SC ...